Humira Biosimilar Gross-to-Net Pricing Bubble Was Preceded by the Same Pricing Bubble Burst for Insulin Just Months Ago

Today ' s post is not about diabetes per se, although there IS a diabetes connection. But this morning, the big news was that a biosimilar of Abbvie ' s blockbuster anti-inflammatory biologic Humira will be sold byMark Cuban Cost Plus Drug Company (see the press release athttps://www.globenewswire.com/news-release/2023/06/01/2680351/33333/en/Mark-Cuban-Cost-Plus-Drug-Company-joins-forces-with-Coherus-to-make-YUSIMRY-a-HUMIRA-biosimilar-available-to-patients.html for more) at what amounts to an 85% discount to the innovator drug. Mark Cuban Cost Plus Drug Company announced the Humira biosimilar on social media today. See the Tweet thread below, or by visiting https://twitter.com/costplusdrugs/status/1664269466535092226?s=20.Learn about our work with@Coherus_Bio:https://t.co/Nc6bmtb7Bb— Mark Cuban Cost Plus Drug Company (@costplusdrugs)June 1, 2023While there are seven biosimilars of Humira which have been approved by FDA (seehttps://www.pharmaceutical-technology.com/features/humira-biosimilars-set-the-stage-for-long-awaited-2023-us-launches/), many were approved but delayed due to patents which were due to expire before the biosimilars could come to market, hence so far, none of the Humira biosimilars which have launched have been particularly aggressive on prices.Until now!Abbvie ' s Humira is currently the best-selling prescription drug in the U.S.. More than 300,000 patients in the U.S. take Humira each year, and it costs the U.S. healthcare system a stunning $90,000...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 Abbvie Biosimilar drug discounts gross-to-net bubble Humira insulin Source Type: blogs